{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:26:55Z","timestamp":1784579215350,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/leu.2014.85","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T07:42:24Z","timestamp":1393400544000},"page":"1570-1572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia"],"prefix":"10.1038","volume":"28","author":[{"given":"M W","family":"Drummond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Boissinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Cauchy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C P","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Szubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P N","family":"Cockerill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D T","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,26]]},"reference":[{"key":"BFleu201485_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223\u2013232.","journal-title":"Lancet Oncol"},{"key":"BFleu201485_CR2","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","volume":"11","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11: 3604\u20133608.","journal-title":"Clin Cancer Res"},{"key":"BFleu201485_CR3","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1002\/cncr.25759","volume":"117","author":"R Costa","year":"2011","unstructured":"Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011; 117: 2690\u20132696.","journal-title":"Cancer"},{"key":"BFleu201485_CR4","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.leukres.2012.04.024","volume":"36","author":"M Thorpe","year":"2012","unstructured":"Thorpe M, Montalvao A, Pierdomenico F, Moita F, Almeida A . Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res 2012; 36: 1071\u20131073.","journal-title":"Leuk Res"},{"key":"BFleu201485_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","volume":"37","author":"L Ades","year":"2013","unstructured":"Ades L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 2013; 37: 609\u2013613.","journal-title":"Leuk Res"},{"key":"BFleu201485_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"B Cheson","year":"2006","unstructured":"Cheson B, Greenberg P, Bennett J, Lowenberg B, Wijermans P, Nimer S et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419\u2013425.","journal-title":"Blood"},{"key":"BFleu201485_CR7","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. IARC Press: Lyon, France, 2008."},{"key":"BFleu201485_CR8","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","volume":"88","author":"E Wattel","year":"1996","unstructured":"Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996; 88: 2480\u20132487.","journal-title":"Blood"},{"key":"BFleu201485_CR9","doi-asserted-by":"publisher","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","volume":"113","author":"FH Grand","year":"2009","unstructured":"Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182\u20136192.","journal-title":"Blood"},{"key":"BFleu201485_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722\u2013726.","journal-title":"Nat Genet"},{"key":"BFleu201485_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","volume":"119","author":"J Score","year":"2012","unstructured":"Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms. Blood 2012; 119: 1208\u20131213.","journal-title":"Blood"},{"key":"BFleu201485_CR12","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","volume":"118","author":"T Braun","year":"2011","unstructured":"Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011; 118: 3824\u20133831.","journal-title":"Blood"},{"key":"BFleu201485_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52\u201357.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201485","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:25:17Z","timestamp":1648743917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,26]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["BFleu201485"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.85","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,26]]},"assertion":[{"value":"26 February 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MWD, JK and DTB have received advisory board and speaker fees from Celgene. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}